Elevated PAI-1 levels are associated with insulin resistance, endothelial dysfunction, liver fibrosis, and elevated cardiovascular risk, making this inhibitor a key systemic indicator of metabolic derangement [6]. This evidence concerns the gene SERPINE1 and Insulin resistance.